Investor Relations

Company Overview

Bionomics (NASDAQ:BNOX, ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing proprietary, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”).

Bionomics has a strategic partnership with Merck & Co., Inc with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Bionomics is currently based in Australia and the US and listed on the Australian Securities Exchange (ASX) under the ticker “BNO“, and trades in the US on NASDAQ Global Market (NASDAQ) under the ticker “BNOX”.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

* Price per AD

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Latest Quarterly or Annual Filing

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

View Filing View All SEC Filings

Email Alerts